Koskivuo Ilkka, Suominen Erkki, Niinikoski Juha, Talve Lauri
Department of Surgery, Turku University Hospital, P.O. Box 52, 20521, Turku, Finland.
Langenbecks Arch Surg. 2005 Sep;390(5):403-7. doi: 10.1007/s00423-005-0572-5. Epub 2005 Jul 29.
Sentinel lymph node biopsy (SLNB) has been widely accepted as a precise tool to stage melanoma. In thin T1 melanomas (<or=1 mm), the indication of SLNB is controversial since the risk of nodal metastasis is low. The aim of this study was to assess if SLNB detects occult nodal metastases among patients with thin melanomas.
SLNB was performed prospectively in 135 patients with invasive melanoma in any depth category, including 56 T1 melanomas.
Nodal metastases were detected in 18% by SLNB, and there were three sentinel-positive thin melanomas, constituting 5% of the T1 cases. Histopathologically, there were no factors of the primary tumors that would have predicted these metastases.
SLNB is a precise method to detect clinically silent nodal metastases in thin invasive melanoma. Certain histopathologic features of a thin primary lesion may correlate with the predictive probability of the sentinel node status. We were unable to identify these predictors, but the conclusions from this study are limited by the small sample size. Advanced melanoma is a lethal disease, and accurate staging is essential also in the T1 group. For stage III patients with occult nodal metastases, metastasectomy is a better option for cure than observation.
前哨淋巴结活检(SLNB)已被广泛认可为黑色素瘤分期的精确工具。在厚度较薄的T1期黑色素瘤(≤1mm)中,由于淋巴结转移风险较低,SLNB的应用指征存在争议。本研究的目的是评估SLNB能否检测出薄型黑色素瘤患者的隐匿性淋巴结转移。
前瞻性地对135例不同深度的浸润性黑色素瘤患者进行了SLNB,其中包括56例T1期黑色素瘤患者。
SLNB检测出18%的患者存在淋巴结转移,有3例前哨淋巴结阳性的薄型黑色素瘤,占T1期病例的5%。在组织病理学上,原发性肿瘤没有任何因素可以预测这些转移。
SLNB是检测薄型浸润性黑色素瘤临床隐匿性淋巴结转移的精确方法。薄型原发性病变的某些组织病理学特征可能与前哨淋巴结状态的预测概率相关。我们未能识别出这些预测因素,但本研究的结论因样本量小而受到限制。晚期黑色素瘤是一种致命疾病,准确分期在T1组中也至关重要。对于存在隐匿性淋巴结转移的III期患者,转移灶切除术比观察更有利于治愈。